Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $49.1 million.

  • Entrada Therapeutics' Cash from Investing Activities rose 159.22% to $49.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year increase of 327.07%. This contributed to the annual value of -$27.8 million for FY2024, which is 79.91% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Cash from Investing Activities stood at $49.1 million, which was up 45.31% from $33.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Cash from Investing Activities registered a high of $53.4 million during Q4 2024, and its lowest value of -$181.5 million during Q1 2022.
  • Its 3-year average for Cash from Investing Activities is -$7.1 million, with a median of $4.8 million in 2025.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 2,119.08% in 2024, then soared by 238.61% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Cash from Investing Activities (Quarterly) stood at $18.8 million in 2022, then climbed by 1.34% to $19.0 million in 2023, then skyrocketed by 180.23% to $53.4 million in 2024, then spiked by 159.22% to $49.1 million in 2025.
  • Its Cash from Investing Activities was $49.1 million in Q3 2025, compared to $33.8 million in Q2 2025 and $4.8 million in Q1 2025.